A next generation NNRTI

New data about IDX899, an experimental next generation NNRTI, was presented at the conference showing reduced viral load in test tube studies both in wild-type HIV and strains with NNRTI-resistance mutations. The drug demonstrated a high barrier to resistance. IDX899 also showed favourable safety in healthy HIV-negative volunteers.

The design of this proof-of- concept study had 30 participants who were randomly assigned to receive IDX899 monotherapy at one of three oral doses – 200 mg, 400mg or 800mg once daily – or else a placebo for seven days. All patients receiving IDX899 after seven days achieved significant drops in viral load. Dr Carlos Zala, from the University of Buenos Aires, who presented the study, reported that IDX899 side effects were generally mild and similar to those seen in the placebo-treated patients and that it was well tolerated and demonstrated potent HIV- 1 antiviral activity at all tested doses.

Zala C, et al. IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naive HIV-1-infected subjects. 17th International AIDS Conference, Mexico City, Abstract THAB04O2, 2008.

Text size: A A A

From Positive Living

This article was first published in September 2008.

While the content of this article was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

More stories from this issue.

This article contains medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Posted online: 24 September 2008.
Last updated: 24 September 2008.

More stories about: